

REMARKS

The present amendment cancels claims 101 and 108 to 111. Claims 80 and 95 have been amended to correct typographical errors. New method claims 112 to 150 are identical to various pending method claims except that each is limited to use of one of the pharmaceutical compositions of claims 87, 88, 90 and 91. No new matter has been added.

No new matter has been added.

Double Patenting Rejections

Claims 1, 5, 8-13 and 20 were provisionally rejected for obviousness-type double patenting over various claims of co-pending applications (U.S. Serial Nos. 10/899,806; 10/845,895; and 10/766,735). Appropriate individual terminal disclaimers over U.S. Serial Nos. 10/899,806, U.S. Serial No. 10/845,895 and U.S. Serial No. 10/766,735 are enclosed.

It is believed that the claims are in condition for allowance. Please apply any other charges or credits to deposit account 06-1050.

Respectfully submitted,

Date: 13 August 2007

/Anita L. Meiklejohn/
Anita L. Meiklejohn, Ph.D.
Reg. No. 35,283

Fish & Richardson P.C.
225 Franklin Street
Boston, MA 02110
Telephone: (617) 542-5070
Facsimile: (617) 542-8906